Table 2.

Characteristics of patients who developed VAEs vs those without VAEs

Characteristicn (%)POR (95% CI)
Patients with VAEs (n = 26)Patients without VAEs (n = 194)
Male/female 15/11 115/79 .99 0.94 (0.4-2) 
Age at nilotinib commencement, y   .014*  
 Median 61 53   
 Range 37-80 21-91   
Duration of nilotinib therapy to time of first VAE, mo  NA   
 Median 19    
 Range 1-68    
Mean no. of cardiovascular risk factors per patient 1.7 0.9 <.001  
Individual cardiovascular risk factors     
 Diabetes 3 (12) 19 (10) .73 1.2 (0.3-4.3) 
 Hypertension 12 (46) 52 (26) .06 2.3 (0.9-5.3) 
 Smoking history (former or current) 14 (54) 59 (30) .025 2.7 (1.2-6.4) 
 History of VAEs 5 (20) 20 (10) .19 2.1 (0.8-5.8) 
 Dyslipidemia 8 (31) 13 (7) <.001* 6.1 (2.2-17.2) 
Line of therapy     
 First 9 (35) 67 (35) .99  
 Second 17 (65) 95 (49) .15  
  First-line therapy, imatinib 17 90   
  First-line therapy, dasatinib   
 Third 0 (0) 32 (16) .018  
Nilotinib dose at commencement, mg     
 800 16 (62) 90 (46) .21  
 600 10 (38) 80 (41) .84  
 400 0 (0) 15 (8) .39  
 300 0 (0) 6 (3) .99  
 150 0 (0) 2 (1) .99  
 Data not available 0 (0) 1 (1) .99  
Characteristicn (%)POR (95% CI)
Patients with VAEs (n = 26)Patients without VAEs (n = 194)
Male/female 15/11 115/79 .99 0.94 (0.4-2) 
Age at nilotinib commencement, y   .014*  
 Median 61 53   
 Range 37-80 21-91   
Duration of nilotinib therapy to time of first VAE, mo  NA   
 Median 19    
 Range 1-68    
Mean no. of cardiovascular risk factors per patient 1.7 0.9 <.001  
Individual cardiovascular risk factors     
 Diabetes 3 (12) 19 (10) .73 1.2 (0.3-4.3) 
 Hypertension 12 (46) 52 (26) .06 2.3 (0.9-5.3) 
 Smoking history (former or current) 14 (54) 59 (30) .025 2.7 (1.2-6.4) 
 History of VAEs 5 (20) 20 (10) .19 2.1 (0.8-5.8) 
 Dyslipidemia 8 (31) 13 (7) <.001* 6.1 (2.2-17.2) 
Line of therapy     
 First 9 (35) 67 (35) .99  
 Second 17 (65) 95 (49) .15  
  First-line therapy, imatinib 17 90   
  First-line therapy, dasatinib   
 Third 0 (0) 32 (16) .018  
Nilotinib dose at commencement, mg     
 800 16 (62) 90 (46) .21  
 600 10 (38) 80 (41) .84  
 400 0 (0) 15 (8) .39  
 300 0 (0) 6 (3) .99  
 150 0 (0) 2 (1) .99  
 Data not available 0 (0) 1 (1) .99  

NA, not applicable.

*

Significant (P < .05) on multivariate analysis.

Percentage indicates percentage of patients receiving that line or dose.

Close Modal

or Create an Account

Close Modal
Close Modal